Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG): the ENTRUST Study

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG): the ENTRUST Study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegozafermin (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENTRUST
  • Sponsors 89bio

Most Recent Events

  • 04 Mar 2025 According to 89bio media release,The trial will now be unblinded after study completion at Week 52 vs. Week 26 following discussions with the FDA. The company also expects to report topline data from ENTRUST in the first quarter of 2026.
  • 13 Jan 2025 According to a 89bio media release, trial completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG) and topline 26-week data expected in the second half of 2025.
  • 13 Jan 2025 Status changed to active, no longer recruiting, according to according to a 89bio media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top